Literature DB >> 22110186

Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling.

Xiaohua Gao1, Yongbo Liu, Dorrah Deeb, Ali S Arbab, Austin M Guo, Scott A Dulchavsky, Subhash C Gautam.   

Abstract

Synthetic oleanane triterpenoids are novel agents which have shown strong antitumorigenic activity against a wide range of cancer types in vitro. The objective of the present study was to determine the anticancer activity of methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me) derived from CDDO, a synthetic analog of oleanolic acid, and its mechanism of action in killing of human ovarian cancer cells. CDDO-Me strongly inhibited the growth of ovarian cancer cells by inducing apoptosis characterized by increased annexin V binding, cleavage of poly (ADP-ribose) polymerase (PARP-1) and procaspases-3, -8 and -9. In addition, CDDO-Me induced mitochondrial depolarization. Western blot analysis showed inhibition of prosurvival (antiapoptotic) phospho-AKT (p-AKT), nuclear factor kappa B (NF-κB) (p65) and phospho-mammalian target of rapamycin (p-mTOR) signaling proteins in cells treated with CDDO-Me. Abrogation of AKT which regulates both NF-κB and mTOR increased the sensitivity of tumor cells to CDDO-Me. Thus, these data showing strong growth-inhibitory and apoptosis-inducing activity of CDDO-Me for ovarian cancer cells through the inhibition of AKT/ NF-κB/mTOR signaling pathway provide basis for evaluation of CDDO-Me for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22110186      PMCID: PMC3711099     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  24 in total

1.  The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta.

Authors:  Mark M Yore; Karen T Liby; Tadashi Honda; Gordon W Gribble; Michael B Sporn
Journal:  Mol Cancer Ther       Date:  2006-12-05       Impact factor: 6.261

2.  Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells.

Authors:  Xiaohua Gao; Dorrah Deeb; Jiang Hao; Yongbo Liu; Ali S Arbab; Scott A Dulchavsky; Subhash C Gautam
Journal:  Anticancer Res       Date:  2010-03       Impact factor: 2.480

Review 3.  The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance.

Authors:  M W Mayo; A S Baldwin
Journal:  Biochim Biophys Acta       Date:  2000-03-27

4.  Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.

Authors:  T Honda; B V Rounds; L Bore; H J Finlay; F G Favaloro; N Suh; Y Wang; M B Sporn; G W Gribble
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

5.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Authors:  J P Neijt; S A Engelholm; M K Tuxen; P G Sorensen; M Hansen; C Sessa; C A de Swart; F R Hirsch; B Lund; H C van Houwelingen
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

6.  Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling.

Authors:  Dorrah Deeb; Xiaohua Gao; Yongbo Liu; Daniel Jiang; George W Divine; Ali S Arbab; Scott A Dulchavsky; Subhash C Gautam
Journal:  Carcinogenesis       Date:  2011-02-16       Impact factor: 4.944

7.  CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.

Authors:  Zhenfeng Duan; Rachel Y Ames; Meagan Ryan; Francis J Hornicek; Henry Mankin; Michael V Seiden
Journal:  Cancer Chemother Pharmacol       Date:  2008-06-28       Impact factor: 3.333

8.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance.

Authors:  Takashi Ikeda; Michael Sporn; Tadashi Honda; Gordon W Gribble; Donald Kufe
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism.

Authors:  Dorrah Deeb; Xiaohua Gao; Hao Jiang; Branislava Janic; Ali S Arbab; Yon Rojanasakul; Scott A Dulchavsky; Subhash C Gautam
Journal:  Biochem Pharmacol       Date:  2009-09-24       Impact factor: 5.858

10.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Authors:  Karen Liby; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Mark M Yore; Tadashi Honda; Gordon W Gribble; Ethan Dmitrovsky; Thomas A Sporn; Michael B Sporn
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

View more
  16 in total

1.  The role of natural products in revealing NRF2 function.

Authors:  Donna D Zhang; Eli Chapman
Journal:  Nat Prod Rep       Date:  2020-05-13       Impact factor: 13.423

Review 2.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

Review 3.  Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Authors:  Karen T Liby; Michael B Sporn
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

4.  Oleanolic acid derivatives induce apoptosis in human leukemia K562 cell involved in inhibition of both Akt1 translocation and pAkt1 expression.

Authors:  Shuhua Pan; Jun Hu; Tingting Zheng; Xinyuan Liu; Yong Ju; Chuanlian Xu
Journal:  Cytotechnology       Date:  2014-04-12       Impact factor: 2.058

5.  ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells.

Authors:  Xiaohua Gao; Yongbo Liu; Dorrah Deeb; Patricia Liu; Annie Liu; Ali S Arbab; Subhash C Gautam
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

6.  Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells.

Authors:  Dong-Jun Qin; Cai-Xia Tang; Li Yang; Hu Lei; Wei Wei; Ying-Ying Wang; Chun-Min Ma; Feng-Hou Gao; Han-Zhang Xu; Ying-Li Wu
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

Review 7.  Targeting nrf2-mediated gene transcription by triterpenoids and their derivatives.

Authors:  Agnieszka Loboda; Ewa Rojczyk-Golebiewska; Barbara Bednarczyk-Cwynar; Zaprutko Lucjusz; Alicja Jozkowicz; Jozef Dulak
Journal:  Biomol Ther (Seoul)       Date:  2012-11       Impact factor: 4.634

Review 8.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.

Authors:  Yan-Yang Wang; Yin-Xue Yang; Hong Zhe; Zhi-Xu He; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

9.  AECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT and suppression of Cancer Stem Cell characteristics.

Authors:  Aparajita Dasgupta; Mithila A Sawant; Gayatri Kavishwar; Manish Lavhale; Sandhya Sitasawad
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

Review 10.  Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.

Authors:  Yan-Yang Wang; Hong Zhe; Ren Zhao
Journal:  Mol Cancer       Date:  2014-02-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.